GlassScriptPhysician profile
Bruce Charles Stein
NPI 1790779320
$151,074.59
in general payments reported to CMS, 2019-2025
23 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $12K · 2021: $15K · 2022: $54K · 2023: $12K · 2024: $15K · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $1,209 · Food and Beverage: $1,177 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,320.00 |
| Travel and Lodging | $1,209.39 |
| Food and Beverage | $1,177.39 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149,726.19 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $276.29 | 2019-2025 | |
| Cvrx, INC. | $208.09 | 2024 | Barostim Neo System |
| Abbott Laboratories | $140.42 | 2022-2025 | Aveir |
| Novo Nordisk INC | $95.36 | 2024 | Ozempic, Wegovy |
| Medtronic Vascular, INC. | $83.63 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $67.45 | 2021-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $53.32 | 2019 | |
| Penumbra, INC. | $45.00 | 2025 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $43.53 | 2019 | |
| Impulse Dynamics (USA) INC. | $42.10 | 2022 | |
| Pfizer INC. | $38.71 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $34.79 | 2022 | |
| Irhythm Technologies, INC. | $30.30 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Becton, Dickinson and Company | $25.59 | 2025 | Venclose Maven Catheter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.66 | 2025 | |
| Bridgebio Pharma, INC. | $24.33 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.14 | 2025 | |
| Medtronic, INC. | $22.72 | 2024 | Turbohawk |
| Bard Peripheral Vascular, INC. | $20.65 | 2019 | |
| Esperion Therapeutics, INC. | $18.40 | 2024 | Nexletol |
| Amgen INC. | $16.31 | 2024 | Repatha |
| Ge Healthcare | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.